FDA Grants Accelerated Approval to Zongertinib for Non-squamous NSCLC with HER2 Tyrosine Kinase Domain Activating Mutations By Ogkologos - August 29, 2025 485 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the Beamion LUNG-1 study Source RELATED ARTICLESMORE FROM AUTHOR Adding Epcoritamab to Lenalidomide and Rituximab Results in Higher Response Rate and Longer PFS in Patients with Relapsed or Refractory Follicular Lymphoma Patient Guide in Prostate Cancer Now Available in Vietnamese One Dose of Either a Bivalent or Nonavalent HPV Vaccine Provides Protection Against HPV16 or HPV18 Infection and Is Not Inferior To Two Doses MOST POPULAR Treatment Benefit with Quizartinib, a Potent and Specific FLT3 Inhibitor for... May 2, 2023 Active Monitoring Promising for Women with Low-Risk Ductal Carcinoma In Situ January 8, 2025 Combining Enzalutamide with Radium-223 Significantly Improves rPFS as First-Line Therapy for... August 27, 2025 Diving into our role in 50 top cancer drugs February 9, 2022 Load more HOT NEWS Chemotherapy Administered for the First Diagnosed Testicular Cancer Reduces the Risk... PROs Support Switching to Camizestrant Plus CDK4/6 Inhibitor for HR-positive, HER2-negative... Significant OS Benefit with Glofitamab plus GemOx in Transplant-Ineligible Patients with... Adjuvant mRNA-4157 Plus Pembrolizumab Prolongs RFS versus Pembrolizumab Alone in Patients...
